ClinicalTrials.gg
Status unknownNCT03313544Updated Apr 21, 2023

Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1

A Phase 4 interventional study of Nivolumab and MRI in Melanoma, Non-small Cell and Lung Cancer, sponsored by Assistance Publique Hopitaux De Marseille. Status unknown at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-21.

Sponsored by Assistance Publique Hopitaux De Marseille · Phase 4, Interventional, and Diagnostic

The sponsor has not verified this record recently (last verified Apr 2023), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 142 studies testing nivolumab in Melanoma — 32 open to participants now, 62 under way, 9 of them phase 3. Nivolumab · Melanoma.

Planned enrollment
68th of 142
50 · median 50
Started
2018
with 7 others
Phase 4
4 of 142
2 open now
Registered
53rd of 142
by date

Among the 142 studies testing nivolumab in Melanoma, this one is the 68th largest by planned enrollment, is one of 8 that started in 2018, is one of 4 in phase 4, and was the 53rd registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.

Browse Melanoma studies →

Open to participants now

32 of the 142 studies testing nivolumab in Melanoma are open now, in 12 countries. Recruiting first, the newest first:

27 more — sign in →

By country, each count listing its studies:

All 32 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies testing nivolumab in Melanoma, or all of them as a file.
02

Study summary

Prospective, monocentric clinical study. Patients selected for nivolumab therapy in AP-HM for melanoma and non-small cell lung cancer will be eligible. Do not include patients with conditions that do not allow MRI, prior cardiovascular disease with LVEF\<50%, cardiomyopathy, history of cardiac arrhythmia, history of cardiovascular toxicity under anticancer therapy, coronary artery disease or stroke less than 3 months Therapeutic management will not be modified and treatment will be administrated as usual.

Cardiovascular follow up will be identical to that recommended and realized in current care in the Cardio-Oncology unit of AP-HM. It will include clinical, biological (BNP and troponin) and trans-thoracic echocardiography (TTE) at baseline and then at 1, 3 and 6 months. Auto-antibodies against troponin I assay will be performed to avoid false negatives of normal blood level of troponin I at baseline and then at 6 months. Cardiac MRI will be performed as well at baseline and at the end of the study (6 months). MRI is the gold standard for ventricular function evaluation.

Primary endpoint will be left ventricular function evolution evaluated by global longitudinal strain (GLS, 2D speckles tracking) in TTE. Secondary endpoints will be left and right ventricular function parameters: LEVF by TTE and MRI, left ventricular indexed volumes by TTE and MRI, right ejection ventricular function and indexed volumes by TTE and MRI, systolic pulmonary arterial pressure by TTE, serum troponin I and BNP, arrhythmias and conduction disorders on the electrocardiogram (ECG).

Number of required subjects: GLS is recommended for following up left ventricular function under anticancer treatments. Based on the hypothesis of a significant GLS decrease (15%) in 20% of cases with alpha risk of 0.05 and accuracy of 0.12 which means expected confidence interval of 0.08-0.32, then the number of required subjects is 50 patients.

The inclusion period will be 18 months with a follow up if 6 months, ie a total duration of the study of 24 months.

03

Conditions studied

  • Melanoma
  • Non-small Cell
  • Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

patients treated with nivolumab

Exclusion criteria

Exclusion Criteria:

  • Age \<18 years
  • Preliminary cardiac disease with FeVG \<50%
  • Cardiomyopathy dilated, hypertrophic or restrictive
  • History of cardiac arrhythmia
  • History of cardiac toxicity under another anti-cancer treatment
  • Known coronary disease
  • History of stroke less than 3 months old
  • Patient not wishing to participate in the study
  • Vulnerable persons (pregnant women, adults under guardianship or guardianship, persons deprived of their liberty)
05

Study design

Phase
Phase 4
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    NIVOLUMAB PATIENTS

    Drug: Nivolumab · Device: MRI · Biological: BLOOD SAMPLES · Device: trans-thoracic echocardiography

Interventions

  • NIVOLUMAB

  • DeviceMRI

    Cardiac MRI 6 MONTHS

  • BiologicalBLOOD SAMPLES

    biological (BNP and troponin)

  • Devicetrans-thoracic echocardiography

    1, 3 and 6 months

06

What researchers measure

Primary outcomes

  1. systolic pulmonary arterial pressure

    trans-thoracic echocardiography

    Time frame: 6 months

Secondary outcomes

  1. ventricular function evaluation.

    MRI

    Time frame: 6 MONTHS

  2. serum troponin I

    BLOOD SAMPLES

    Time frame: 1,3, 6 months

  3. Brain natriuretic peptide (BNP)

    BLOOD SAMPLES

    Time frame: 1,3, 6 months

07

Study locations

1 of 1 sites recruiting
  • Assistance Publique Hopitaux de Marseille
    Marseille, 13354, France
    Recruiting
08

References and documents

Publications

  • Cadour F, Cautela J, Rapacchi S, Varoquaux A, Habert P, Arnaud F, Jacquier A, Meilhac A, Paganelli F, Lalevee N, Scemama U, Thuny F. Cardiac MRI Features and Prognostic Value in Immune Checkpoint Inhibitor-induced Myocarditis. Radiology. 2022 Jun;303(3):512-521. doi: 10.1148/radiol.211765. Epub 2022 Mar 1. PubMed 35230185 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2018 (actual). Primary completion is estimated for Oct 2024, 78 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2017
First posted
Oct 18, 2017
StartActual
Apr 9, 2018
Primary completionEst.
Oct 2024
CompletionEst.
Mar 2025
Last update
Apr 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03313544
Responsible party
Sponsor
First posted
Oct 18, 2017
Start date
Apr 9, 2018
Primary completion
Oct 2024 (estimated)
Completion
Mar 2025 (estimated)
Last update
Apr 21, 2023

Study contacts

jennifer CAUTELA
Contact
jennifer.cautela@ap-hm.fr
0491968289
ALEXANDRA GIULIANI
Contact
drci@ap-hm.fr
0491382747
Jean-Olivier ARNAUD
study director · assistance publique hôpitaux de marseille

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion